St Baldrick'S Foundation Inc

“The organization has contracted with an outside cpa to prepare its form 990 from information furnished by the organization. After receiving the draft return from the outside accountants, the organization's cfo and executive director reviewed the draft. The draft was then distributed to the organization's board of directors for a period of comment before management and the cpa firm finalized the return.”

“All board members are required to sign an annual conflict of interest disclosure form and notify the Chairman of the Board if circumstances change during the year.”

“The compensation committee reviews the Executive Director's job performance and accomplishments against the related goals and performance expectations set every year. Any salary adjustment is forwarded to the entire Board as a recommendation and requires approval from the Board of Directors. Additionally, the Chief Financial Officer's compensation is reviewed annually by the Executive Director and the Compensation Committee. Any adjustment to the Chief Financial Officer's compensation is also forwarded to the entire Board as a recommendation and requires approval from the Board of Directors.”

“The organization provides its audited financial statements to the public on its website. Governing documents and the conflict of interest policy are available upon request.”

“Donated services used = -$518921”

“Increase in temporarily restricted net assets = $92500”

“The Foundation makes disease specific grants as well as grants aimed at multiple childhood cancers and St. Baldrick's has funded grants to study all 12 major types of childhood cancers as well as many sub-types. In FY 2014, grants were awarded in the following categories:Scholars - $6,026,321Consortium Research Grants - $4,040,868Fellowships - $2,007,994Infrastructure - $2,292,113International Scholars - $330,000Research Grants - $900,000Pediatric Dream Team - $1,875,000Summer Fellows - $105,000Supportive Care Research - $150,000COG - $7,543,708GENIUS - $610,000These categories were created both to advance research and to respond to the ever-worsening level of federal research, and the need to increase pediatric cancer funding from industry. These needs, unique to the pediatric cancer population prioritize the funding of clinical trials, building the capacity of institutions to participate in research and make the best therapies available to their patients, educating the next generation of researcher, translating research done in a lab to actual patients, and new discovery research. The Foundation also addresses the widely unmet research needs of adolescent and young adult patients, as well as improving the quality of life of survivors as 95% of survivors will have a chronic health problem by the age of 45 as a result of treatment during childhood, and on improving the quality of life during treatment, including symptom management, family coping skills and compliance with therapy. As a result of our efforts, numerous findings and publications have occurred, as well as significant advancements in treatment including:A new cure for Neuroblastoma, raising survival from 33% to 50%Tumor paint is being developed to help surgeons see cancerous tissue that might otherwise remain undetected, while doing surgery.An improved cure rate for most common type of childhood cancer, Acute Lymphoblastic Leukemia, from 80% to 90% survival.Raising cure rate from 20% to 70% for a rare type of childhood cancer, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.For childhood cancers that are both difficult to cure and uncommon, many research institutions have not been able to devote the resources necessary to open important clinical trials. And our 2012 grant to the Childrens Oncology Group (COG) directly resulted in 130 research institutions opening four of these high-impact studies. Together with Stand Up to Cancer, St. Baldricks has also funded the worlds first pediatric cancer dream team with a grant of $14.5 million over four years. St. Baldricks commitment is $7.5 million for this grant which will combat four of the most difficult to cure cancers high-risk neuroblastoma, sarcomas, brain tumors, acute myeloid leukemia, and refractory acute lymphoblastic leukemia. The 7 institutions comprising this team are bringing together two scientific areas that have, until now, been evolving on parallel tracks: genomics (the study of genes and their functions) and immunotherapeutics (using the bodys own immune system to attack cancer).”